Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 31 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate CancerCompletedNCT04100018Phase 3Results posted
• Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving OsimertinibTerminatedNCT04099836Phase 2Results posted
• An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer PatientsCompletedNCT04099641Phase 2Results posted
• Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C MelanomaActive, not recruitingNCT04099251Phase 3Results posted
• Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)CompletedNCT04098068Phase 2Results posted
• Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast CancerTerminatedNCT04095689Phase 2Results posted
• Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory MelanomaTerminatedNCT04093323Phase 2Results posted
• Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced MelanomaActive, not recruitingNCT04091750Phase 2Results posted
• Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal MelanomaCompletedNCT04091217Phase 2Results posted
• pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate CancerActive, not recruitingNCT04090528Phase 2Results posted
• Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal AdenocarcinomaTerminatedNCT04089904Phase 2Results posted
• A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell CarcinomaTerminatedNCT04088500Phase 2Results posted
• Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid CancersCompletedNCT04082572Phase 2Results posted
• Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerCompletedNCT04082364Phase 2/3Results posted
• Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLCTerminatedNCT04081688Phase 1Results posted
• Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine TumorsActive, not recruitingNCT04079712Phase 2Results posted
• Durvalumab Long-Term Safety and Efficacy StudyCompletedNCT04078152Phase 4Results posted
• A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast CancerCompletedNCT04075604Phase 2Results posted
• Talazoparib and Avelumab in Participants With Metastatic Renal Cell CarcinomaCompletedNCT04068831Phase 2Results posted
• Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal AntibodyCompletedNCT04068519Phase 1/2Results posted
• Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).CompletedNCT04068181Phase 2Results posted
• A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLCCompletedNCT04063163Phase 3Results posted
• CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung CancerActive, not recruitingNCT04062708Phase 2Results posted
• Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant TumorsCompletedNCT04056910Phase 2Results posted
• Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid TumorsTerminatedNCT04052204Phase 1/2Results posted
• Nivolumab Combined With BMS-986253 in HCC PatientsTerminatedNCT04050462Phase 2Results posted
• Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid TumorsTerminatedNCT04049617Phase 1Results posted
• Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid TumorsCompletedNCT04047862Phase 1Results posted
• A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted TherapiesCompletedNCT04042558Phase 2Results posted
• Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal CancerActive, not recruitingNCT04034927Phase 2Results posted
• Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung CancerActive, not recruitingNCT04032418Phase 2Results posted
• Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal CancerActive, not recruitingNCT04030455Phase 2Results posted
• A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by SurgeryCompletedNCT04026412Phase 3Results posted
• A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung CancerActive, not recruitingNCT04025879Phase 3Results posted
• Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)Active, not recruitingNCT04021108Phase 2Results posted
• BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver CancersCompletedNCT04021043Phase 1/2Results posted
• Nivolumab in Biochemically Recurrent dMMR Prostate CancerCompletedNCT04019964Phase 2Results posted
• AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT04019288Phase 1/2Results posted
• Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First RecurrenceCompletedNCT04013672Phase 2Results posted
• A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)Active, not recruitingNCT04008030Phase 3Results posted
• Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive GlioblastomaTerminatedNCT04006119Phase 2Results posted
• Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT04005716Phase 3Results posted
• Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder CancerCompletedNCT04004221Phase 2Results posted
• Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)CompletedNCT04003636Phase 3Results posted
• Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)TerminatedNCT04003610Phase 2Results posted
• Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung CancerCompletedNCT04003246Phase 2Results posted
• A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaActive, not recruitingNCT03999749Phase 2Results posted
• Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149TerminatedNCT03997448Phase 2Results posted
• An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid CancersCompletedNCT03994601Phase 1/2Results posted
• PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid TumorsTerminatedNCT03993379Phase 2Results posted
• Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck CancerCompletedNCT03993353Phase 2Results posted
• High Dose IL-2 in Combination With Anti-PD-1TerminatedNCT03991130Phase 2Results posted
• Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)TerminatedNCT03990961Phase 2Results posted
• Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic CarcinomaCompletedNCT03990571Phase 2Results posted
• Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell CarcinomaTerminatedNCT03988647Phase 2Results posted
• A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal CancerCompletedNCT03981146Phase 2Results posted
• Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.CompletedNCT03980925Phase 2Results posted
• Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder CancerActive, not recruitingNCT03978624Phase 2Results posted
• Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 InhibitorCompletedNCT03977467Phase 2Results posted
• Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)CompletedNCT03976375Phase 3Results posted
• Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)CompletedNCT03971474Phase 2Results posted
• This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.TerminatedNCT03968419Phase 2Results posted
• IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for MelanomaTerminatedNCT03958383Phase 1/2Results posted
• Combination Rucaparib With Nivolumab in Small Cell Lung CarcinomaCompletedNCT03958045Phase 2Results posted
• A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaCompletedNCT03957590Phase 3Results posted
• Cabozantinib and Pembrolizumab for Advanced Metastatic MelanomaTerminatedNCT03957551Phase 1/2Results posted
• Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian CancerTerminatedNCT03955471Phase 2Results posted
• De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal CancerActive, not recruitingNCT03952585Phase 2/3Results posted
• Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension StudyCompletedNCT03950674Phase 3Results posted
• A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).TerminatedNCT03946670Phase 2Results posted
• De-Escalation Therapy for Human Papillomavirus Negative DiseaseCompletedNCT03944915Phase 2Results posted
• A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced CancerTerminatedNCT03936959Phase 1Results posted
• Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyCompletedNCT03933449Phase 3Results posted
• Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced MelanomaActive, not recruitingNCT03929029Phase 1Results posted
• Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell LymphomaCompletedNCT03927105Phase 2Results posted
• Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)CompletedNCT03924986Phase 3Results posted
• Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)Active, not recruitingNCT03924895Phase 3Results posted
• Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)TerminatedNCT03924869Phase 3Results posted
• A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid LeukemiaTerminatedNCT03922477Phase 1Results posted
• IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction CancerCompletedNCT03918499Phase 1/2Results posted
• GEN1046 Safety Trial in Patients With Malignant Solid TumorsTerminatedNCT03917381Phase 1/2Results posted
• Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung CancerCompletedNCT03916419Phase 2Results posted
• Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial CancerActive, not recruitingNCT03914612Phase 3Results posted
• Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid CancerActive, not recruitingNCT03914300Phase 2Results posted
• A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCTActive, not recruitingNCT03912064Phase 1Results posted
• Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple MyelomaTerminatedNCT03910439Phase 2Results posted
• Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaActive, not recruitingNCT03907488Phase 3Results posted
• Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung CancerTerminatedNCT03906071Phase 3Results posted
• Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain MetastasisTerminatedNCT03903640Phase 2Results posted
• High-Risk Skin Cancers With Atezolizumab Plus NT-I7TerminatedNCT03901573Phase 1/2Results posted
• A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue SarcomasCompletedNCT03899805Phase 2Results posted
• Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal CancerCompletedNCT03894891Phase 2Results posted
• SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or LymphomasCompletedNCT03894618Phase 1Results posted
• Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder CancerCompletedNCT03892642Phase 1/2Results posted
• Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)CompletedNCT03884101Phase 3Results posted
• Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHNCompletedNCT03878979Phase 2Results posted
• Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)Active, not recruitingNCT03875235Phase 3Results posted
• A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension StudyCompletedNCT03875092Phase 3Results posted
• Aromatase Inhibitor and Durvalumab in Postmenopausal Breast CancerTerminatedNCT03874325Phase 2Results posted
• Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the BrainCompletedNCT03873818Phase 2Results posted

← Immune Checkpoint Inhibitors overview